Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |
---|---|
First Received Date † | June 20, 2003 |
Last Updated Date | August 22, 2008 |
Start Date † | |
Current Primary Outcome Measures † | |
Original Primary Outcome Measures † | |
Change History | Complete list of historical versions of study NCT00063154 on ClinicalTrials.gov Archive Site |
Current Secondary Outcome Measures † | |
Original Secondary Outcome Measures † | |
Descriptive Information | |
Brief Title † | Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy |
Official Title † | A Phase II, Open-Label, Multicenter Study to Evaluate the Effect of Tumor-Based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Recurrent Non-Small Cell Lung Cancer |
Brief Summary | The purpose of this study is to determine if the study drug pertuzumab is effective in treating patients with advanced lung cancer that has recurred following prior chemotherapy. |
Detailed Description | |
Study Phase | Phase II |
Study Type † | Interventional |
Study Design † | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Condition † | Non-Small Cell Lung Cancer |
Intervention † | Drug: rhuMAb 2C4 (pertuzumab) |
Study Arms / Comparison Groups | |
Publications * | |
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|
Recruitment Information | |
Recruitment Status † | Completed |
Enrollment † | 60 |
Completion Date | December 2004 |
Primary Completion Date | |
Eligibility Criteria † | Inclusion Criteria:
Each lesion must be >= 20 mm when measured by conventional techniques, including palpation, plain X-ray, CT, and MRI, or >= 10 mm when measured by spiral CT.
Exclusion Criteria:
|
Gender | Both |
Ages | 18 Years and older |
Accepts Healthy Volunteers | No |
Contacts †† | |
Location Countries † | United States |
Expanded Access Status | |
Administrative Information | |
NCT ID † | NCT00063154 |
Responsible Party | |
Secondary IDs †† | |
Study Sponsor † | Genentech |
Collaborators †† | |
Investigators † | |
Information Provided By | Genentech |
Verification Date | August 2008 |
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |